SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bossi A.) "

Sökning: WFRF:(Bossi A.)

  • Resultat 1-10 av 60
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Schael, S, et al. (författare)
  • Precision electroweak measurements on the Z resonance
  • 2006
  • Ingår i: Physics Reports. - : Elsevier BV. - 0370-1573 .- 1873-6270. ; 427:5-6, s. 257-454
  • Forskningsöversikt (refereegranskat)abstract
    • We report on the final electroweak measurements performed with data taken at the Z resonance by the experiments operating at the electron-positron colliders SLC and LEP. The data consist of 17 million Z decays accumulated by the ALEPH, DELPHI, L3 and OPAL experiments at LEP, and 600 thousand Z decays by the SLID experiment using a polarised beam at SLC. The measurements include cross-sections, forward-backward asymmetries and polarised asymmetries. The mass and width of the Z boson, m(Z) and Gamma(Z), and its couplings to fermions, for example the p parameter and the effective electroweak mixing angle for leptons, are precisely measured: m(Z) = 91.1875 +/- 0.0021 GeV, Gamma(Z) = 2.4952 +/- 0.0023 GeV, rho(l) = 1.0050 +/- 0.0010, sin(2)theta(eff)(lept) = 0.23153 +/- 0.00016. The number of light neutrino species is determined to be 2.9840 +/- 0.0082, in agreement with the three observed generations of fundamental fermions. The results are compared to the predictions of the Standard Model (SM). At the Z-pole, electroweak radiative corrections beyond the running of the QED and QCD coupling constants are observed with a significance of five standard deviations, and in agreement with the Standard Model. Of the many Z-pole measurements, the forward-backward asymmetry in b-quark production shows the largest difference with respect to its SM expectation, at the level of 2.8 standard deviations. Through radiative corrections evaluated in the framework of the Standard Model, the Z-pole data are also used to predict the mass of the top quark, m(t) = 173(+10)(+13) GeV, and the mass of the W boson, m(W) = 80.363 +/- 0.032 GeV. These indirect constraints are compared to the direct measurements, providing a stringent test of the SM. Using in addition the direct measurements of m(t) and m(W), the mass of the as yet unobserved SM Higgs boson is predicted with a relative uncertainty of about 50% and found to be less than 285 GeV at 95% confidence level. (c) 2006 Elsevier B.V. All rights reserved.
  •  
2.
  • Schael, S., et al. (författare)
  • Electroweak measurements in electron positron collisions at W-boson-pair energies at LEP
  • 2013
  • Ingår i: Physics Reports. - : Elsevier BV. - 0370-1573 .- 1873-6270. ; 532:4, s. 119-244
  • Forskningsöversikt (refereegranskat)abstract
    • Electroweak measurements performed with data taken at the electron positron collider LEP at CERN from 1995 to 2000 are reported. The combined data set considered in this report corresponds to a total luminosity of about 3 fb(-1) collected by the four LEP experiments ALEPH, DELPHI, 13 and OPAL, at centre-of-mass energies ranging from 130 GeV to 209 GeV. Combining the published results of the four LEP experiments, the measurements include total and differential cross-sections in photon-pair, fermion-pair and four-fermion production, the latter resulting from both double-resonant WW and ZZ production as well as singly resonant production. Total and differential cross-sections are measured precisely, providing a stringent test of the Standard Model at centre-of-mass energies never explored before in electron positron collisions. Final-state interaction effects in four-fermion production, such as those arising from colour reconnection and Bose Einstein correlations between the two W decay systems arising in WW production, are searched for and upper limits on the strength of possible effects are obtained. The data are used to determine fundamental properties of the W boson and the electroweak theory. Among others, the mass and width of the W boson, m(w) and Gamma(w), the branching fraction of W decays to hadrons, B(W -> had), and the trilinear gauge-boson self-couplings g(1)(Z), K-gamma and lambda(gamma), are determined to be: m(w) = 80.376 +/- 0.033 GeV Gamma(w) = 2.195 +/- 0.083 GeV B(W -> had) = 67.41 +/- 0.27% g(1)(Z) = 0.984(-0.020)(+0.018) K-gamma - 0.982 +/- 0.042 lambda(gamma) = 0.022 +/- 0.019. (C) 2013 Elsevier B.V. All rights reserved.
  •  
3.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
4.
  • Ferrario, M., et al. (författare)
  • IRIDE : Interdisciplinary research infrastructure based on dual electron linacs and lasers
  • 2014
  • Ingår i: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 740, s. 138-146
  • Tidskriftsartikel (refereegranskat)abstract
    • This paper describes the scientific aims and potentials as well as the preliminary technical design of RUDE, an innovative tool for multi-disciplinary investigations in a wide field of scientific, technological and industrial applications. IRIDE will be a high intensity "particles factory", based on a combination of high duty cycle radio-frequency superconducting electron linacs and of high energy lasers. Conceived to provide unique research possibilities for particle physics, for condensed matter physics, chemistry and material science, for structural biology and industrial applications, IRIDE will open completely new research possibilities and advance our knowledge in many branches of science and technology. [RIDE is also supposed to be realized in subsequent stages of development depending on the assigned priorities.
  •  
5.
  • Horwich, A, et al. (författare)
  • EAU–ESMO consensus statements on the management of advanced and variant bladder cancer - an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committees
  • 2019
  • Ingår i: Annals of Oncology. - : Oxford University Press. - 0923-7534 .- 1569-8041. ; 30:11, s. 1697-1727
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.SETTING: Online Delphi survey and consensus conference.PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.
  •  
6.
  •  
7.
  •  
8.
  • Anastasi, A., et al. (författare)
  • Combination of KLOE sigma (e(+) e(-) -> pi(+)pi(-) gamma(gamma)) measurements and determination of a(mu)(pi+pi-) in the energy range 0.10 < s < 0.95 GeV2
  • 2018
  • Ingår i: Journal of High Energy Physics (JHEP). - : Springer. - 1126-6708 .- 1029-8479. ; :3
  • Tidskriftsartikel (refereegranskat)abstract
    • The three precision measurements of the cross section sigma (e(+)e(-) -> pi(+)pi(-)gamma(gamma)) using initial state radiation by the KLOE collaboration provide an important input for the prediction of the hadronic contribution to the anomalous magnetic moment of the muon. These measurements are correlated for both statistical and systematic uncertainties and, therefore, the simultaneous use of these measurements requires covariance matrices that fully describe the correlations. We present the construction of these covariance matrices and use them to determine a combined KLOE measurement for sigma (e(+)e(-) -> pi(+)pi(-)gamma(gamma)). We find, from this combination, a two-pion contribution to the muon magnetic anomaly in the energy range 0.10 < s < 0.95 GeV2 of a(mu)(pi+pi-) (489.8 +/- 1.7(stat) +/- 4.8(sys)) x 10(-10).
  •  
9.
  • Anastasi, A., et al. (författare)
  • Combined limit on the production of a light gauge boson decaying into mu(+) mu(-) and pi(+) pi(-)
  • 2018
  • Ingår i: Physics Letters B. - : ELSEVIER SCIENCE BV. - 0370-2693 .- 1873-2445. ; 784, s. 336-341
  • Tidskriftsartikel (refereegranskat)abstract
    • We searched for the mu(+) mu(-) decay of a light vector gauge boson, also known as dark photon, in the e(+) e(-) -> mu(+) mu(-) gamma(ISR) process by means of the Initial State Radiation (ISR) method. We used 1.93fb(-1) of data collected by the KLOE experiment at the DA Phi NE phi-factory. No structures have been observed over the irreducible mu(+) mu(-) background. A 90% CL limit on the ratio epsilon(2)= alpha'/alpha between the dark coupling constant and the fine structure constant of 3 x 10(-6)-2 x 10(-7) has been set in the dark photon mass region between 519 MeV and 973 MeV. This new limit has been combined with the published result obtained investigating the hypothesis of the dark photon decaying into hadrons in e(+) e(-) -> pi(+) pi(-) gamma(ISR) events. The combined 90% CL limit increases the sensitivity especially in the rho-omega interference region and excludes epsilon(2) greater than (13 - 2) x 10(-7). For dark photon masses greater than 600 MeV the combined limit is lower than 8 x 10(-7) resulting more stringent than present constraints from other experiments.
  •  
10.
  • Anastasi, A., et al. (författare)
  • Limit on the production of a new vector boson in e+e− → Uγ, U → π+π− with the KLOE experiment
  • 2016
  • Ingår i: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 757, s. 356-361
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract The recent interest in a light gauge boson in the framework of an extra U(1) symmetry motivates searches in the mass range below 1 GeV. We present a search for such a particle, the dark photon, in e + e − → U γ , U → π + π − based on 28 million e + e − → π + π − γ events collected at DAΦNE by the KLOE experiment. The π + π − production by initial-state radiation compensates for a loss of sensitivity of previous KLOE U → e + e − , μ + μ − searches due to the small branching ratios in the ρ – ω resonance region. We found no evidence for a signal and set a limit at 90% CL on the mixing strength between the photon and the dark photon, ε 2 , in the U mass range between 527 and 987 MeV . Above 700 MeV this new limit is more stringent than previous ones.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 60
Typ av publikation
tidskriftsartikel (54)
forskningsöversikt (4)
doktorsavhandling (2)
Typ av innehåll
refereegranskat (56)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
Bossi, F. (29)
Graziani, E. (27)
Ceradini, F. (25)
Di Domenico, A. (25)
Passeri, A. (25)
Schioppa, M. (25)
visa fler...
Miscetti, S. (25)
Domenici, D. (25)
Bloise, C. (25)
De Santis, A. (25)
Giovannella, S. (25)
Martini, M. (25)
Silarski, M. (25)
Babusci, D. (25)
Dané, E. (25)
Wolke, Magnus (24)
Tortora, L. (24)
Mandaglio, G. (24)
De Lucia, E. (24)
Venanzoni, G. (24)
Wiślicki, W. (24)
Gauzzi, P. (23)
Kupsc, Andrzej (23)
Johansson, Tord (23)
Patera, V (23)
Czerwinski, E. (23)
Fiore, S. (23)
Messi, R. (23)
Moricciani, D. (23)
Budano, A (23)
Branchini, P. (22)
Moskal, P. (21)
Ciambrone, P. (20)
Curciarello, F. (20)
De Leo, V. (20)
Felici, G. (19)
De Simone, P (19)
Bencivenni, G. (19)
Santangelo, P. (19)
Ranieri, A. (19)
Morello, G. (18)
Fantini, A. (18)
Happacher, F. (17)
Sarra, I. (17)
Di Cicco, A. (17)
Gajos, A. (17)
Giardina, G. (16)
Loffredo, S. (15)
Mascolo, M. (15)
Krzemien, W. (14)
visa färre...
Lärosäte
Uppsala universitet (28)
Karolinska Institutet (11)
Linköpings universitet (10)
Lunds universitet (5)
Umeå universitet (4)
Stockholms universitet (4)
visa fler...
Göteborgs universitet (2)
Linnéuniversitetet (2)
Kungliga Tekniska Högskolan (1)
visa färre...
Språk
Engelska (60)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (29)
Medicin och hälsovetenskap (9)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy